{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:28:36Z","timestamp":1780568916675,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018748","name":"argenx nv","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jns.2026.125918","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:25:35Z","timestamp":1776011135000},"page":"125918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20"],"prefix":"10.1016","volume":"486","author":[{"given":"Peter D.","family":"Donofrio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Gorson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chafic","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Kira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kostera-Pruszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"L\u00e9ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Nobile-Orazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Attarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Markov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"De Roeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jns.2026.125918_bb0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40120-020-00184-6","article-title":"The misdiagnosis of CIDP: a review","volume":"9","author":"Allen","year":"2020","journal-title":"Neurol. Ther."},{"issue":"17","key":"10.1016\/j.jns.2026.125918_bb0010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.21037\/atm.2018.07.34","article-title":"Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies","volume":"6","author":"Roggenbuck","year":"2018","journal-title":"Ann. Transl. Med."},{"issue":"10","key":"10.1016\/j.jns.2026.125918_bb0015","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.125918_bb0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jns.12455","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision","volume":"26","author":"Van den Bergh","year":"2021","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"6","key":"10.1016\/j.jns.2026.125918_bb0025","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/ene.14796","article-title":"Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"28","author":"Broers","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2026.125918_bb0030","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.0000000000001833","article-title":"CIDP diagnostic pitfalls and perception of treatment benefit","volume":"85","author":"Allen","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2026.125918_bb0035","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/WCO.0000000000001414","article-title":"Controversies in the diagnosis of chronic inflammatory demyelinating polyneuropathy","volume":"38","author":"Doneddu","year":"2025","journal-title":"Curr. Opin. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2026.125918_bb0040","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","volume":"17","author":"Van den Bergh","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.125918_bb0045","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00415-024-12860-w","article-title":"Early therapy initiation is crucial in chronic inflammatory demyelinating polyneuropathy: prospective multimodal data from the German INHIBIT registry","volume":"272","author":"Schumacher","year":"2025","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2026.125918_bb0050","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S1474-4422(19)30144-9","article-title":"Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"18","author":"Bunschoten","year":"2019","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.jns.2026.125918_bb0055","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1007\/s00415-020-09998-8","article-title":"Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"268","author":"Querol","year":"2021","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2026.125918_bb0060","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s12325-020-01540-6","article-title":"A global survey of disease burden in patients who carry a diagnosis of chronic inflammatory demyelinating polyneuropathy","volume":"38","author":"Allen","year":"2021","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.jns.2026.125918_bb0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1529-8027.2010.00284.x","article-title":"Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice","volume":"15","author":"Gorson","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"2","key":"10.1016\/j.jns.2026.125918_bb0070","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00415-021-10677-5","article-title":"Clinical outcome of CIDP one year after start of treatment: a prospective cohort study","volume":"269","author":"Bus","year":"2022","journal-title":"J. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2026.125918_bb0075","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/cei.12518","article-title":"Adverse effects of immunoglobulin G therapy: thromboembolism and haemolysis","volume":"178","author":"Bonilla","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.jns.2026.125918_bb0080","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1093\/cid\/ciad474","article-title":"Unintended consequences: risk of opportunistic infections associated with long-term glucocorticoid therapies in adults","volume":"78","author":"Chastain","year":"2024","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.jns.2026.125918_bb0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1468-1331.2009.02802.x","article-title":"A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"17","author":"Cocito","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2026.125918_bb0090","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jns.2026.125918_bb0095","series-title":"Diagnostic adjudication of chronic inflammatory demyelinating polyneuropathy (CIDP) in the ADHERE trial: first 200 cases, AANEM annual meeting, Nashville, TN, USA","author":"Donofrio","year":"2022"},{"issue":"2","key":"10.1016\/j.jns.2026.125918_bb0100","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/jnnp-2018-318714","article-title":"Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database","volume":"90","author":"Doneddu","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2026.125918_bb0105","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13063-021-05083-1","article-title":"Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC)","volume":"22","author":"Bus","year":"2021","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.jns.2026.125918_bb0110","doi-asserted-by":"crossref","DOI":"10.2196\/17117","article-title":"Efficacy and safety of rituximab in refractory CIDP with or without IgG4 autoantibodies (RECIPE): protocol for a double-blind, randomized, placebo-controlled clinical trial","volume":"9","author":"Shimizu","year":"2020","journal-title":"JMIR Res. Protoc."},{"issue":"4","key":"10.1016\/j.jns.2026.125918_bb0115","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/brain\/awae400","article-title":"Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial","volume":"148","author":"Nobile-Orazio","year":"2025","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.jns.2026.125918_bb0120","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/jnnp-2022-329357","article-title":"Comparison of the diagnostic accuracy of the 2021 EAN\/PNS and 2010 EFNS\/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"93","author":"Doneddu","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2026.125918_bb0125","series-title":"Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","author":"ClinicalTrials.gov","year":"2025"},{"key":"10.1016\/j.jns.2026.125918_bb0130","series-title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis (ADAPT SERON)","author":"ClinicalTrials.gov","year":"2025"}],"updated-by":[{"DOI":"10.1016\/j.jns.2026.125965","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000}},{"DOI":"10.1016\/j.jns.2026.125965","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000}}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26002005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26002005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:26:51Z","timestamp":1778722011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26002005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"alternative-id":["S0022510X26002005"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125918","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic adjudication of potential participants with chronic inflammatory demyelinating polyradiculoneuropathy in the ADHERE trial of subcutaneous efgartigimod PH20","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"125918"}}